← Eichor
Study identifier: NCT06141187 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Percutaneous Vertebroplasty Vs. Sham for Osteoporotic Vertebral Compression Fractures Focusing on Pain and Economy.

Condition: Osteoporotic Fractures · Vertebral Fracture  ·  Sponsor: Spine Centre of Southern Denmark

PhaseNA
Planned participants240
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this randomized double-blind clinical trial is to determine the efficacy of percutaneous vertebroplasty (PVP) in relieving severe pain in patients with MRI-verified acute or sub-acute osteoporotic vertebral compression fractures (OVCFs) compared to sham as well as examine the socio-economic implications associated with performing vertebroplasty. The primary outcome is improvement of pain intensity as measured on a Visual Analog Scale (VAS, 0 to100) 12 weeks after treatment. Secondary outcomes include patient-reported back-related disability, patient-reported quality of life, spinal sagittal balance, complications associated with the procedure, incidence of new OVCFs and socioeconomic costs.

This description comes directly from the study's public registry record.

Talk to the study team

Mikkel Ø Andersen, MD  ·  +45 2320 9173  ·  mikkel.andersen2@rsyd.dk

Always discuss trial participation with your own doctor first.

Locations (1)

Rygcenter SyddanmarkMiddelfart, Fyn, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06141187